User login
A supplement to Family Practice News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.
•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience
To view the supplement, click the image above.
Topics
• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis
Faculty/Faculty Disclosure Statement
Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.
Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.
Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.
James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.
Target Audience
This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.
Copyright © 2006 Elsevier Inc.
A supplement to Family Practice News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.
•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience
To view the supplement, click the image above.
Topics
• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis
Faculty/Faculty Disclosure Statement
Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.
Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.
Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.
James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.
Target Audience
This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.
Copyright © 2006 Elsevier Inc.
A supplement to Family Practice News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.
•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience
To view the supplement, click the image above.
Topics
• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis
Faculty/Faculty Disclosure Statement
Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.
Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.
Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.
James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.
Target Audience
This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.
Copyright © 2006 Elsevier Inc.
